A c c e p t e d M a n u s c r i p t such as tenofovir and ritonavir-boosted protease inhibitors (PI) 4 . The accurate estimation of glomerular filtration rate (GFR) using endogenous filtration markers is critical for the clinical care of these patients, but is impaired in chronic HIV-infection by significant non-GFR determinants of creatinine and the novel marker cystatin C [5] [6] [7] .
Both CKD 8 and HIV infection 9 are characterized by high levels of systemic inflammation; however, whether inflammation is a significant non-GFR determinant of cystatin C levels that explains the strong associations of cystatin C with clinical outcomes in HIV infection is unclear 7, 10 . Statins have anti-inflammatory effects in HIV-uninfected patients with CKD 8, 11 , but the ability to slow GFR decline appears to be quite modest 12 .
In HIV infection, statins have decreased inflammation and immune activation markers in some studies, with varying results depending on the biomarker studied and ART status [13] [14] [15] [16] [17] [18] . To our knowledge, no study has evaluated the effect of statin therapy on glomerular function or cystatin C in HIV-infected patients.
The objectives of this study were two-fold. First, we aimed to examine the baseline cross-sectional associations of cystatin C levels with markers of inflammation and subclinical vascular disease among HIV-infected patients on ART enrolled in a randomized trial of statin therapy. Second, we studied the 24-week effect of rosuvastatin by Jules Levin on July 12, 2014 http://cid.oxfordjournals.org/
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A c c e p t e d M a n u s c r i p t 5 on cystatin C levels and estimated GFR and whether changes in cystatin C were related to changes in inflammation markers.
Methods
The Stopping Atherosclerosis and Treating Unhealthy Bone with RosuvastatiN in HIV (SATURN-HIV) trial is a randomized, double-blind, placebo-controlled trial that was designed to study the effect of rosuvastatin 10mg daily on vascular and bone health.
Randomization was stratified by use of protease inhibitor at study entry. Secondary prespecified endpoints include biomarkers of inflammation and immune activation, including cystatin C, and changes in renal function. All subjects were ≥18 years of age without known coronary disease or diabetes, and on stable ART for at least 3 months with HIV-1 RNA <1,000 copies/mL. In a similar design as the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) study in HIV-uninfected adults 19 , entry criteria included LDL-cholesterol ≤130mg/dL and evidence of increased inflammation and/or T-cell activation (high sensitivity C-reactive protein ≥2mg/L and/or CD8+CD38+HLA-DR+ T-cells ≥19%). Participants with creatinine clearance <50 mL/min by Crockoft-Gault were excluded. Full inclusion and exclusion are listed at clinicaltrials.gov (NCT01218802). The study was approved by the Institutional Review Board of University Hospitals Case Medical Center (Cleveland, Ohio) and all participants signed written informed consent. 
Study evaluations
Demographics and medical history were obtained by self-report and review of past medical records. A targeted physical exam and 12-hour fasting blood draw were performed at each visit (screening, 0, and 24 weeks). Peripheral blood mononuclear cells (PBMCs) were separated by centrifugation with Ficoll-Hypaque and were cryopreserved until analyzed by flow cytometry in batch. Frozen plasma samples were stored at -80°C and analyzed in batch. Baseline evaluations also included a whole body dual-energy absorptiometry (DEXA) scan for peripheral and trunk fat 20 . Insulin resistance was calculated from fasting glucose and insulin using the homeostatic model assessment of insulin resistance (HOMA-IR) 21 . Ten-year Framingham risk score was determined using a published risk calculator 22 .
Cystatin C and kidney function
Plasma cystatin C concentration was measured by particle enhanced immunonepholometric assay on a BNII nephelometer (Siemens, Munich, Germany) at the University of Vermont Laboratory for Clinical Biochemistry Research. Inter-assay variability ranged from 2.0-2.8%. Serum creatinine was measured by the enzymatic method in the University Hospitals clinical chemistry laboratory on a VISTA 1500 integrated system (Siemens, Munich, Germany). Glomerular filtration rate (eGFR cr ) was 26, 27 and is reported in units of 10
Eight categories of subclinical vascular disease phenotype 24 were pre-specified according to the presence of one or more of the following: (1) coronary atherosclerosis defined as the presence of any detectable coronary artery calcium (CAC) by CT; (2) carotid atherosclerosis defined as the presence of plaque or a mean-max CCA-IMT >1.0mm, or (3) abnormal endothelial function defined as having below median values of both FMD (<4%) and hyperemic VTI (<77cm). Monocytes and T-cells were phenotyped by flow cytometry as previously described 28, 29 . Three monocyte subsets: (1) CD14+CD16+, (2) CD14 dim CD16+, and (3) CD14+CD16-were each quantified as a percentage of the overall monocyte population.
T-cell activation was quantified as the percentage of CD4+ or CD8+ cells that expressed both CD38 and HLA-DR.
Statistical Analysis
This study is a pre-specified cross-sectional analysis of the relationship of cystatin C levels to markers of cardiovascular risk and inflammation and a longitudinal analysis of 0-24 week changes in cystatin C and eGFR.
Demographics, HIV parameters, cardiac and metabolic factors are described overall and by group using median and interquartile range (IQR) for continuous variables and frequency and percent for categorical variables. All baseline variables were Between and within-group changes in cystatin C and eGFR cr were tested using paired t-tests or Wilcoxon Signed Rank tests as distributionally appropriate. ANCOVA was used to adjust mean percent change in cystatin c over 24 weeks for age, sex, PI use, baseline eGFR cr with and without change in eGFR cr . Adjusted means were compared using unpaired t tests. 
Results
Of 202 participants who were screened, 147 participants were randomized to receive rosuvastatin 10mg daily (n=72) or matching placebo (n=75). Reasons for screen failure and loss to follow-up (n=11) have been described previously 13, 15 (see Supplemental Figure) . Over the first 24 weeks of the trial, one subject switched ART from didanosine to abacavir and one switched from lamivudine/zidovudine to emtricitabine/tenofovir plus maraviroc.
The baseline characteristics of the randomized participants are displayed in Table   1 and were similar between treatment groups (all p>0.05). Overall, median (interquartile range) age was 46 (40, 53) years; 78% were male, 68% African American, and 14% had hepatitis C. Tenofovir and protease inhibitors (PI) were used in 88% and 49% of subjects, respectively. Median eGFR cr was 100 (87, 118) mL/min/1.73m A c c e p t e d M a n u s c r i p t 11 cardiometabolic risk factors and higher levels of generalized inflammation and immune activation in this population 25 . After adjustment for age, sex, and race, higher cystatin C was independently associated with thicker CCA-IMT (p=0.029) and larger epicardial adipose tissue volume (p=0.02).
As reported previously, over two-thirds of this population had endothelial dysfunction or subclinical atherosclerosis in at least one vascular bed 24 . Figure 2A (Table 3) . Importantly, cystatin C levels remained independently associated with soluble TNF-α receptors and sICAM-1 in a model that included estimated GFR (Table 3 ). Other independent associations were observed with eGFR cr , systolic blood pressure, and protease inhibitor use. Tenofovir use was not associated with baseline cystatin C in univariable analyses (p=0.99), nor when it was added to the final multivariable model (p=0.77). was a decrease in eGFR cr in the placebo group but not in the rosuvastatin group, with a significant between group difference (Figure 2) . In ANCOVA analyses of cystatin C changes, adjustment for PI use and baseline eGFR cr did not change the results; however, after adjustment for 0-24 week change in eGFR cr , the difference between statin and placebo arms was no longer statistically significant (p=0.099). Changes in cystatin C concentration were correlated with changes in sTNF-RI receptors in both arms of the study; whereas significant correlations with changes in CD4+ T-cell activation and sICAM-1 were only observed in the statin arm (Table 4) . Within the statin arm, changes in cystatin C did not correlate with changes in LDL cholesterol (r=-0.1274, p=0.3056).
Discussion
In this randomized clinical trial of HIV-infected patients on ART, 10mg of daily rosuvastatin decreased plasma cystatin C levels and preserved creatinine-based eGFR.
Interestingly, plasma cystatin C was associated with inflammation and endothelial activation at baseline independent of eGFR cr , and changes in cystatin C correlated with changes in inflammation, endothelial activation, and T-cell activation. This trial provides the first evidence in patients with HIV-infection that statin therapy may have salutary effects on kidney function, and also suggests that some of the effect on plasma cystatin C levels may be related to changes in systemic inflammation and immune activation. In a combined analysis of pravastatin trials 32 , pravastatin 40mg daily decreased the rate of eGFR loss by 8% overall, and by 34% among those with moderate CKD (eGFR 30-60mL/min/1.73m 2 ). In the CARE (Cholesterol and Recurrent Events) trial 35 , the most "inflamed" participants (highest tertile of CRP and sTNF-RI) derived the greatest renal benefit from pravastatin. Consistent with these findings from CARE, our study suggests that HIV-infected subjects with elevated markers of inflammation despite effective ART are a sub-group of patients that may gain a protective renal benefit from statins.
The extent to which cystatin C changes in our study were due to changes in eGFR is not clear. Although adjustment for eGFR cr attenuated the observed changes in cystatin C, there was still a trend towards statistical significance. It is possible that residual Redistribution and Metabolic Change (FRAM), cystatin C was a potent independent predictor of mortality 39 , but was not related to carotid intima media thickness after adjustment for age, sex, and race 40 . In our study, plasma cystatin C levels were associated with multiple measures of subclinical vascular disease in univariable analyses.
Adjustment for age, sex, and race removed the association with some measures, although CCA-IMT and epicardial adipose tissue remained independently associated with cystatin C. Our study adds to these results by including endothelial function testing and coronary calcium scoring to provide a more complete phenotype of vascular structure and function.
The highest cystatin C levels were seen in participants with the combination of brachial endothelial dysfunction, detectable coronary calcium, and carotid disease.
The major strength of our study was the double-blind, placebo-controlled randomized trial design. In addition, the extent of inflammation, immune activation, and subclinical vascular disease in the study subjects were very well characterized. The study was limited by the lack of a gold-standard direct measure of GFR. The study may have lacked power to detect an effect of statin therapy on cystatin C that is independent of eGFR cr . We chose to use the creatinine-based CKD-EPI equation to estimate GFR rather than the cystatin C-based or the combined equation, because we were testing the hypothesis that cystatin C is influenced by inflammation. We recognize that eGFR cr is biased by other non-GFR determinants of creatinine such as muscle mass, which may have influenced our findings. Finally, we did not account for the effect of other potentially nephrotoxic medications besides ART. 
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